| Recruiting | Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure NCT07528274 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377 | EpiBiologics | Phase 1 |
| Recruiting | Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer ( NCT07354061 | Tang-Du Hospital | Phase 1 / Phase 2 |
| Recruiting | Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1 NCT07122258 | Tau Medical Australia Pty Ltd | N/A |
| Not Yet Recruiting | Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC NCT07438600 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 | Radiopharm Theranostics, Ltd | Phase 1 / Phase 2 |
| Enrolling By Invitation | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum- NCT07285434 | Biogenea Pharmaceuticals Ltd. | EARLY_Phase 1 |
| Recruiting | Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup NCT07441941 | Institut du Cancer de Montpellier - Val d'Aurelle | — |
| Not Yet Recruiting | Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial NCT07274384 | Università Vita-Salute San Raffaele | Phase 2 |
| Not Yet Recruiting | Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSC NCT07242274 | Jemincare | Phase 3 |
| Not Yet Recruiting | Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadju NCT07286942 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC NCT07330050 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) NCT07120698 | Guangdong Association of Clinical Trials | Phase 2 |
| Not Yet Recruiting | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or NCT07193160 | Fudan University | Phase 2 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresecta NCT07139041 | Chang Chen | Phase 2 |
| Not Yet Recruiting | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC NCT07182708 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 | West China Hospital | Phase 1 |
| Not Yet Recruiting | Immune-Marker Platform for Patients With Advanced Lung Cancer NCT07150598 | Technische Universität Dresden | — |
| Not Yet Recruiting | Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-p NCT07063329 | Avistone Pharmaceutical（Ningbo）Co., LTD. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer NCT07034365 | Fudan University | — |
| Not Yet Recruiting | A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based NCT06977828 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Me NCT07376707 | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies NCT07327489 | Elephas | — |
| Recruiting | Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Sta NCT06939127 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569 | Alterome Therapeutics, Inc. | Phase 1 |
| Recruiting | Pan-tumor MRD Study NCT06605404 | Paradigm Health | — |
| Recruiting | Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC NCT07003490 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Recruiting | First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy NCT06667167 | Nir Peled | Phase 2 |
| Recruiting | D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N NCT07016126 | Guangdong Provincial People's Hospital | Phase 3 |
| Recruiting | Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clin NCT06684418 | Fudan University | — |
| Recruiting | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC NCT06617416 | Akeso | Phase 3 |
| Active Not Recruiting | Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients NCT06751108 | Seoul National University | — |
| Recruiting | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity o NCT06616766 | Yuhan Corporation | Phase 1 / Phase 2 |
| Recruiting | Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC NCT06863506 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Not Yet Recruiting | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lun NCT06614231 | Sun Yat-sen University | Phase 2 |
| Recruiting | Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor NCT06967532 | Medical University of Vienna | — |
| Recruiting | Study of XB010 in Subjects With Solid Tumors NCT06545331 | Exelixis | Phase 1 |
| Recruiting | A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871 | Iambic Therapeutics, Inc | Phase 1 |
| Recruiting | Cognitive Screening in Lung Cancer Patients NCT06727370 | European Institute of Oncology | — |
| Recruiting | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers NCT05873686 | Nuvectis Pharma, Inc. | Phase 1 |
| Recruiting | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform NCT05520099 | Elephas | — |
| Active Not Recruiting | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors NCT05651022 | Indaptus Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform NCT05478538 | Elephas | — |
| Recruiting | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas NCT05751798 | OSE Immunotherapeutics | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With A NCT05538130 | Pfizer | Phase 1 |
| Completed | IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC) NCT05118334 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tum NCT03562819 | AstraZeneca | — |
| Terminated | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma NCT03207867 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) NCT02572843 | Swiss Cancer Institute | Phase 2 |
| Withdrawn | An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third- NCT02522910 | Yonsei University | Phase 1 / Phase 2 |
| Active Not Recruiting | Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC) NCT06876402 | Hellenic Cooperative Oncology Group | — |
| Completed | A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung NCT01639001 | Pfizer | Phase 3 |